Core Points - Santhera Pharmaceuticals' shareholders approved all motions by the Board of Directors at the Annual General Meeting with a participation representing 5,073,050 shares or 37.5% of the Company's share capital [1] Group 1: Financial Approvals - Shareholders approved the 2024 Annual Report, annual financial statements, and consolidated financial statements, along with the appropriation of the annual result against free reserves [2] - Conditional capital for employee participation was increased by CHF 63,000 to CHF 111,280.20 [3] Group 2: Board Elections - Thomas Meier, Philipp Gutzwiller, and Bradley C. Meyer were re-elected to the Board of Directors for another one-year term, with Thomas Meier also re-elected as Chairman [4] - Melanie Rolli was elected as a new member of the Board, and the Nomination & Compensation Committee members were confirmed [4] Group 3: Compensation Approvals - The Compensation Report for 2024 was endorsed in a consultative vote, and shareholders agreed to the fixed compensation for the Board of Directors and Executive Management for the upcoming periods [5]